Roche

News

After FDA no, Regeneron gets yes from EU on odronextamab

Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US.

News

A pair of spectacles in front of computer screens

Does Roche have buyer's remorse for Flatiron takeover?

Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion.

News

AMPLIFY results dial up Calquence's potential in CLL

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuste

News

European big pharmas raise guidance on stronger sales

AstraZeneca, Roche, and Sanofi released their second-quarter results today, with a common theme – strong sales growth that caused them to raise their financial guidance for the year.

News

Roche reveals first data with Carmot-sourced oral GLP-1 drug

Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of its $3.1 billion takeover of Carmot Therapeutics as it tries to catch up with the leaders in the

News

Roche will relaunch AMD implant Susvimo after update

Roche’s Genentech unit has said will reintroduce its Susvimo implant for eyesight-robbing disease age-related macular degeneration (AMD), which was withdrawn from sale in 2022 due to manufa

After FDA no, Regeneron gets yes from EU on odronextamab

Does Roche have buyer's remorse for Flatiron takeover?

AMPLIFY results dial up Calquence's potential in CLL

European big pharmas raise guidance on stronger sales

Roche reveals first data with Carmot-sourced oral GLP-1 drug

Roche will relaunch AMD implant Susvimo after update

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks